Table II.

Patient characteristics and response to gefitinib or erlotinib therapy.

Case no.	Age (yrs)	Gender	EGFR mutationa	Type of EGFR-TKI	Dose reductionb	Response	Time to progression (days)	Survival (days)	Subsequent therapy	Beyond PDc
1	85	F	L858R	Gefitinib	Yes	PR	260	452	None	Yes
2	85	F	Wild-type	Gefitinib	No	PD	13	70	None	No
3	82	F	L858R	Gefitinib	Yes	PR	224	446	None	Yes
4	81	F	L858R	Gefitinib	Yes	PR	493	865	Pemetrexed	No
5	86	F	Unkown	Gefitinib	Yes	PR	159	192	None	No
6	81	F	Exon 19 del	Gefitinib	Yes	PR	223	371	None	Yes
7	81	M	L858R	Gefitinib	Yes	PR	96	183	None	Yes
8	85	F	Exon 19 del	Gefitinib	Yes	SD	733	854	None	Yes
9	88	F	L858R	Gefitinib	Yes	SD	851	965	None	No
10	83	F	Wild-type	Erlotinib	No	SD	63	99	None	No
11	81	F	Exon 19 del	Gefitinib	Yes	PR	188	734	Erlotinib	No
12	96	M	L858R	Erlotinib	Yes	PR	84	107	None	No
13	86	F	L858R	Gefitinib	Yes	PR	272	710	None	Yes
14	81	M	L858R	Gefitinib	No	SD	554	661	None	No
15	83	F	L858R	Gefitinib	Yes	PR	112	580	Erlotinib	No
16	80	M	Wild-type	Erlotinib	Yes	SD	55	361	Radiation	No
17	85	M	Exon 19 del	Gefitinib	No	PD	12	12	None	No
18	85	M	L858R	Gefitinib	No	PR	66	172	Erlotinib	No
19	90	M	Exon 19 del	Gefitinib	Yes	PR	166	341	Erlotinib	Yes
20	80	M	L858R	Gefitinib	Yes	PR	182	221	None	No
21	89	F	L858R	Gefitinib	No	PR	273	273	None	No

^aL858R: leucine to arginine at codon 858 (e xon 21).

^bDose reduction of EGFR-TKIs due to EGFR-TKI-related adverse events;

^cFirst EGFR-TKI therapy beyond disease progression. M, male; F, female; PR, p a rtial response; SD, stable disease; PD, progressive disease; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.